Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders
CA 2856986 C · Owner: Anthrogenesis Corporation · Inventors: Hariri, Robert J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method of extracting and recovering embryonic like stem cells including, but not limited to pluripotent or multipotent stem cells from an exsanguinated human placenta. A placenta is treated to move residual umbilical cord blood by perfusing an exsanguinated placenta preferably with an anticoagulant solution to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 13, 2002 and granted August 13, 2019. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 13, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 13, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.